Lifesci Capital Issues Pessimistic Outlook for PVLA Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at Lifesci Capital reduced their FY2026 earnings estimates for Palvella Therapeutics in a research report issued to clients and investors on Monday, December 15th. Lifesci Capital analyst S. Slutsky now forecasts that the company will earn ($4.72) per share for the year, down from their previous forecast of ($4.17). The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

PVLA has been the topic of a number of other reports. BTIG Research upped their price target on Palvella Therapeutics from $167.00 to $192.00 and gave the stock a “buy” rating in a research note on Monday. Canaccord Genuity Group upped their target price on Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research report on Tuesday. Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Tuesday. Craig Hallum started coverage on shares of Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 price target for the company. Finally, Truist Financial upped their target price on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $155.60.

Palvella Therapeutics Price Performance

PVLA stock opened at $99.73 on Thursday. The company’s 50-day moving average is $85.80 and its 200-day moving average is $57.18. The stock has a market capitalization of $1.18 billion, a PE ratio of -37.92 and a beta of -0.20. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $112.00.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Institutional Trading of Palvella Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Archer Investment Corp purchased a new position in Palvella Therapeutics in the third quarter worth $28,000. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the 3rd quarter worth $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $37,000. AlphaQuest LLC bought a new position in Palvella Therapeutics during the third quarter valued at about $164,000. Finally, JPMorgan Chase & Co. grew its position in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. 40.11% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

More Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $200 from $120, a strong signal from a sell‑side firm that can boost bullish interest. Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
• Positive Sentiment: TD Cowen raised its price target to $133, adding further upward pressure on the stock via another institutional endorsement. TD Cowen Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00
• Positive Sentiment: Market headlines note an analyst upgrade that coincided with a recent sharp move higher in PVLA shares, which likely amplified buying momentum. Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% After Analyst Upgrade
• Neutral Sentiment: HC Wainwright revised down near‑term EPS forecasts for FY2027–FY2029 (multiple cuts) but kept a “Buy” rating and a $200 price target — a mixed signal that tempers long‑term optimism with weaker near‑term profitability projections.
• Negative Sentiment: Lifesci Capital cut its FY2026 EPS estimate (worse expected losses), a negative revision that could weigh on sentiment if the company misses near‑term expectations.
• Negative Sentiment: COO Kathleen Goin sold 4,302 shares at an average price of $96.47 (SEC filing), a disclosure investors often view as a cautionary sign even if the sale may be for personal reasons. SEC filing

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.